Analysts think ALKS stock price could increase by 12%
Mar 07, 2025, 12:25 PM
-13.28%
What does ALKS do
Alkermes Plc is a biopharmaceutical company based in Dublin, focused on developing treatments for alcohol and opioid dependence, schizophrenia, and bipolar I disorder, employing 2,100 people. Its key products include LYBALVI, ARISTADA, and VIVITROL, with ongoing development for neurological disorders and cancer.
16 analysts think ALKS stock price will increase by 11.86%. The current median analyst target is $38.76 compared to a current stock price of $34.65. The lowest analysts target is $21.21 and the highest analyst target is $48.30.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
